[go: up one dir, main page]

MX2013012579A - Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilicos y metodos para prepararlos y usarlos. - Google Patents

Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilicos y metodos para prepararlos y usarlos.

Info

Publication number
MX2013012579A
MX2013012579A MX2013012579A MX2013012579A MX2013012579A MX 2013012579 A MX2013012579 A MX 2013012579A MX 2013012579 A MX2013012579 A MX 2013012579A MX 2013012579 A MX2013012579 A MX 2013012579A MX 2013012579 A MX2013012579 A MX 2013012579A
Authority
MX
Mexico
Prior art keywords
pharmaceutical agents
lipophilic pharmaceutical
preparing
methods
lipophilic
Prior art date
Application number
MX2013012579A
Other languages
English (en)
Other versions
MX360638B (es
Inventor
Borje S Andersson
Benigno C Valdez
Jeffrey Tarrand
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2013012579A publication Critical patent/MX2013012579A/es
Publication of MX360638B publication Critical patent/MX360638B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se pueden proporcionar las composiciones de agentes farmacéuticos lipofílicos con solubilidad y estabilidad mejoradas. Por ejemplo, se puede proporcionar una composición no acuosa que comprende un agente farmacéutico lipofílico, y un solvente polimérico anfifílico como PEG400 pero esencialmente libre de solventes orgánicos y de partículas no solubilizadas. La composición puede además diluirse con un diluyente acuoso deseado como un fluido de infusión para la administración parenteral a un sujeto como un humano. Las composiciones pueden ser útiles para el tratamiento de las enfermedades o de las condiciones que son sensibles a los agentes lipofílicos, como las enfermedades infecciosas y las enfermedades malignas o autoinmunes.
MX2013012579A 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos. MX360638B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480259P 2011-04-28 2011-04-28
PCT/US2012/034361 WO2012148799A1 (en) 2011-04-28 2012-04-20 Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

Publications (2)

Publication Number Publication Date
MX2013012579A true MX2013012579A (es) 2014-03-26
MX360638B MX360638B (es) 2018-11-12

Family

ID=46045121

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013788A MX380805B (es) 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
MX2013012579A MX360638B (es) 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018013788A MX380805B (es) 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.

Country Status (15)

Country Link
US (5) US9364433B2 (es)
EP (2) EP2701684B1 (es)
JP (2) JP6080312B2 (es)
CN (2) CN103635179B (es)
AR (1) AR086115A1 (es)
AU (1) AU2012250050B2 (es)
CA (1) CA2834262C (es)
DK (2) DK3238709T3 (es)
ES (2) ES2822350T3 (es)
HU (2) HUE034480T2 (es)
IL (1) IL229067B (es)
MX (2) MX380805B (es)
PL (2) PL3238709T3 (es)
TW (1) TWI626059B (es)
WO (1) WO2012148799A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
BR112013015085A8 (pt) * 2010-12-16 2018-04-03 Univ Texas Composição farmacêutica, método para preparar uma composição, e, uso de composição
MX380805B (es) * 2011-04-28 2025-03-12 Univ Texas Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
GR20120100242A (el) * 2012-05-04 2014-01-02 Micrel Ιατρικα Μηχανηματα Α.Ε., Αντλια και προγεμισμενος ασκος/σετ αναλγησιας
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9974860B2 (en) 2013-09-13 2018-05-22 Akiko Itai Aqueous solution formulation and method for manufacturing same
CN112107693B (zh) 2013-12-03 2023-05-26 西北大学 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
WO2015176161A1 (en) 2014-05-23 2015-11-26 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN105394045B (zh) * 2014-09-04 2020-02-14 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
US11266621B1 (en) 2014-10-02 2022-03-08 Exela Sterile Medicines Llc Methocarbamol composition and related methods
WO2016059590A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of small molecule drugs and process for its preparation
TWI516520B (zh) 2014-10-31 2016-01-11 財團法人工業技術研究院 波長轉換聚合物、其製法及包含其之波長轉換裝置
PT3347009T (pt) 2015-07-08 2022-01-12 Triple Hair Inc Composição compreendendo resveratrol e melatonina para reduzir a perda de cabelo e/ou aumentar o crescimento do cabelo
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN105837556B (zh) * 2016-04-11 2018-10-26 上海工程技术大学 一种来那度胺与烟酰胺共晶的制备方法
ES2937307T3 (es) * 2016-07-26 2023-03-27 Univ Southern California Inhibición selectiva del bromodominio del BDF1 fúngico
EP3506906A4 (en) * 2016-08-31 2020-08-12 Taro Pharmaceutical Industries Ltd. TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN106841100A (zh) * 2016-12-28 2017-06-13 北京医药集团有限责任公司 一种基于近红外光谱技术的小规格口服固体制剂中活性药物成分快速测定方法
EP3607074A4 (en) * 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
CA3059435A1 (en) * 2017-04-12 2018-10-18 Synergistic Therapeutics, Llc Therapeutic neuropathic pain lotion
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
EP3852728B1 (en) 2018-09-20 2024-09-18 ModernaTX, Inc. Preparation of lipid nanoparticles and methods of administration thereof
BR112021005104A2 (pt) * 2018-10-16 2021-06-08 US Nano Food & Drug INC formulação de injeção intratumoral
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US20210369669A1 (en) * 2018-10-31 2021-12-02 Systamedic Inc. Autophagy activators and inhibitors of ferroptosis for preventing acute renal failure and neurotoxcity induced by certain antibiotics
CN109627148B (zh) * 2018-11-28 2021-09-03 中国农业科学院麻类研究所 一种大麻二酚的制备方法、制得的大麻二酚及其用途
WO2020183322A1 (en) 2019-03-08 2020-09-17 Taro Pharmaceutical Industries Ltd. Stable topical compositions of fenoldopam
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
WO2021108051A2 (en) * 2019-10-25 2021-06-03 Cmc Pharmaceuticals, Inc. Atropine-scopolamine with enhanced stability
BR112022010879A2 (pt) 2019-12-04 2022-10-18 RESQ Pharmaceuticals LLC Métodos e composições para tratamento de edema refratário a diuréticos orais
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN114181211B (zh) * 2020-09-14 2024-05-28 鲁南制药集团股份有限公司 一种酮咯酸与苯甲酰胺共晶体及其制备方法
CN112697945A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片含量的分析方法
CN113274379B (zh) * 2021-05-25 2023-04-25 湖北工业大学 Bephenium Hydroxynaphthoate在制备抗EV71药物的应用
CN113768937B (zh) * 2021-11-15 2022-04-08 恒翼生物医药科技(上海)有限公司 用于降低尿酸水平的化合物
US20230210857A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations
CN115721607B (zh) * 2022-11-19 2023-07-21 华夏生生药业(北京)有限公司 一种乳酸左氧氟沙星注射液及其制备方法
WO2024153217A1 (en) * 2023-01-20 2024-07-25 Insilico Medicine Ip Limited Inhibitors of kif18a and uses thereof
US20250032417A1 (en) 2023-07-24 2025-01-30 Hyloris Developments Sa Lyophilized metolazone formulation for parenteral administration
WO2025054148A1 (en) * 2023-09-07 2025-03-13 Cfd Research Corporation Co-administration of astemizole and an anticancer agent to treat cancer
CN118121554A (zh) * 2024-03-14 2024-06-04 天津市保灵动物保健品有限公司 盐酸特比萘芬片剂
CN119499175A (zh) * 2024-11-23 2025-02-25 江西赣南海欣药业股份有限公司 一种注射用法莫替丁及其制备方法
CN119951294B (zh) * 2025-02-14 2025-12-16 内蒙古优然牧业有限责任公司 一种用于牧场的生物除臭剂及其制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS475827Y1 (es) 1970-04-02 1972-02-29
JPS475827A (es) * 1971-08-27 1972-03-29
AU461715B2 (en) * 1972-01-21 1975-05-19 American Home Products Corporation Parenteral benzodiazepine compositions
DE3316510A1 (de) 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
DE3702105A1 (de) 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
JPH01242525A (ja) 1988-03-25 1989-09-27 Nippon Nohyaku Co Ltd 抗真菌外用剤
US5430057A (en) 1993-09-30 1995-07-04 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
US5869474A (en) * 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7179475B1 (en) 1998-12-04 2007-02-20 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA01011981A (es) 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB2365770B (en) 2000-08-18 2002-07-31 Diomed Dev Ltd Antifungal ketoconazole composition for topical use
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
JP2002322056A (ja) 2001-04-27 2002-11-08 Nippon Kayaku Co Ltd トリアゾール誘導体の溶液製剤
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
WO2004014431A1 (en) 2002-08-12 2004-02-19 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US9259390B2 (en) 2003-08-13 2016-02-16 The University Of Houston System Parenteral and oral formulations of benzimidazoles
GB0412866D0 (en) 2004-06-09 2004-07-14 Novartis Ag Organic compounds
FR2872703B1 (fr) 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
JP2008514645A (ja) * 2004-09-24 2008-05-08 アールエフイー ファーマ エルエルシー 眼疾患およびその他の疾患の局所的処置のためのｃａｉに基づくシステムおよび方法
CN101155584A (zh) 2005-03-31 2008-04-02 布里斯托尔-迈尔斯斯奎布公司 给药伊沙匹隆的方法
WO2007002761A2 (en) 2005-06-27 2007-01-04 Barrier Therapeutics, Inc. Micogel topical formulations
ITMI20051826A1 (it) 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
US20070082870A1 (en) 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
CN101410098B (zh) 2006-01-23 2012-01-18 耶路撒冷希伯来大学伊森姆研究发展公司 包括含亲脂性药物的纳米胶囊的微球
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
EP2097065A2 (en) 2006-11-29 2009-09-09 Foamix Ltd. Foamable waterless compositions with modulating agents
KR20100075475A (ko) 2007-09-05 2010-07-02 가부시키가이샤 폴라 파마 의약 조성물
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
US20090253712A1 (en) 2008-04-03 2009-10-08 Semmelweis Egyetem Aqueous solvent system for solubilization of azole compounds
WO2009139925A1 (en) 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
US20100197621A1 (en) 2009-02-05 2010-08-05 William Henry Methods of reducing the proliferation and viability of microbial agents
JP5688405B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
BR112013015085A8 (pt) * 2010-12-16 2018-04-03 Univ Texas Composição farmacêutica, método para preparar uma composição, e, uso de composição
MX380805B (es) * 2011-04-28 2025-03-12 Univ Texas Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.

Also Published As

Publication number Publication date
EP2701684B1 (en) 2017-06-14
US20200147076A1 (en) 2020-05-14
JP2017014293A (ja) 2017-01-19
AU2012250050A1 (en) 2013-11-21
CA2834262C (en) 2020-08-25
HK1251983A1 (zh) 2019-05-10
US20120277249A1 (en) 2012-11-01
CN103635179B (zh) 2017-12-29
EP2701684A1 (en) 2014-03-05
ES2822350T3 (es) 2021-04-30
CN103635179A (zh) 2014-03-12
US10028949B2 (en) 2018-07-24
MX360638B (es) 2018-11-12
US10548890B2 (en) 2020-02-04
EP3238709B1 (en) 2020-07-01
CA2834262A1 (en) 2012-11-01
US9724345B2 (en) 2017-08-08
PL2701684T3 (pl) 2018-09-28
US9364433B2 (en) 2016-06-14
DK3238709T3 (da) 2020-09-28
ES2640572T3 (es) 2017-11-03
US20180296556A1 (en) 2018-10-18
IL229067B (en) 2018-03-29
US20160346278A1 (en) 2016-12-01
HUE034480T2 (en) 2018-02-28
DK2701684T3 (en) 2017-09-18
JP2014513094A (ja) 2014-05-29
JP6080312B2 (ja) 2017-02-15
CN107970209B (zh) 2020-10-30
AR086115A1 (es) 2013-11-20
US20170172971A1 (en) 2017-06-22
HK1245665A1 (en) 2018-08-31
US11045466B2 (en) 2021-06-29
WO2012148799A1 (en) 2012-11-01
EP3238709A1 (en) 2017-11-01
AU2012250050B2 (en) 2017-04-06
HUE051400T2 (hu) 2021-03-01
PL3238709T3 (pl) 2021-02-08
IL229067A0 (en) 2013-12-31
TWI626059B (zh) 2018-06-11
TW201247242A (en) 2012-12-01
CN107970209A (zh) 2018-05-01
MX380805B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
MX360638B (es) Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
MX372534B (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
EP4360621A3 (en) Formulations of bendamustine
BR112013003772A2 (pt) composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
IN2014MN02213A (es)
EA201270683A1 (ru) Составы в виде лиофилизированного кека
NZ631345A (en) Pharmaceutical compositions having improved storage stability
WO2014118808A3 (en) Ticagrelor solid dispersion
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
PH12015502556A1 (en) Modified release formulation
MX388073B (es) Composición farmacéutica, preparación y usos de la misma.
WO2016040814A3 (en) Disulfide polymers and methods of use
PH12015500681A1 (en) Non-aqueous taxane nanodispersion formulations and methods of using the same
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
PH12016501117A1 (en) Pharmaceutical compositions of carotenoid
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
GR1008234B (el) Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου
HK1223852A1 (zh) 睪丸酮凝膠組合物及相關方法
EA201500128A1 (ru) Педиатрические жидкие композиции для перорального введения, содержащие непадутант
WO2013171766A3 (en) Saxagliptin solid dispersion
HK1206273A1 (en) Pharmaceutical composition of a papillomavirus inhibitor

Legal Events

Date Code Title Description
FG Grant or registration